News >

Trastuzumab Deruxtecan Shows Promise Beyond Breast and Gastric Tumors

Jessica Hergert
Published: Monday, Mar 30, 2020

Bob T. Li, MD, MPH, an expert in lung cancers at Memorial Sloan Kettering Cancer Center

Bob T. Li, MD, MPH

Fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201), a HER2-directed antibody¬–drug conjugate (ADC), demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types, according to findings from a phase I study (NCT02564900) published in Cancer Discovery.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication